# An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

> **NCT01134666** · — · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 165 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01134666
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-30
- **Primary completion:** 2013-07-31
- **Final completion:** 2014-08-05
- **Target enrollment:** 165 (ACTUAL)
- **Why stopped:** The study was discontinued due to slow recruitment and subjects not completing follow up period.
- **Last updated:** 2017-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134666, "An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01134666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*